Cyclo Therapeutics, Inc. – NASDAQ:CYTH
Cyclo Therapeutics stock price today
$0.721
+0.12
+20.5%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 5 hours
Cyclo Therapeutics stock price monthly change
-52.54%
month
Cyclo Therapeutics stock price quarterly change
-52.54%
quarter
Cyclo Therapeutics stock price yearly change
-63.54%
year
Cyclo Therapeutics key metrics
Market Cap | 16.86M |
Enterprise value | N/A |
P/E | -0.37 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 2.29 |
Price/Book | 6.00 |
PEG ratio | 0.04 |
EPS | -1 |
Revenue | 1.12M |
EBITDA | -20.12M |
Income | -19.39M |
Revenue Q/Q | 32.83% |
Revenue Y/Y | -15.51% |
Profit margin | -144531884.55% |
Oper. margin | -153024910.64% |
Gross margin | -63458428.81% |
EBIT margin | -153024910.64% |
EBITDA margin | -1786.87% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCyclo Therapeutics stock price history
Cyclo Therapeutics stock forecast
Cyclo Therapeutics financial statements
| Jun 2023 | 117.11K | -4.63M | -3958.79% |
|---|---|---|---|
| Sep 2023 | 495.47K | -4.77M | -962.98% |
| Dec 2023 | 311.39K | -5.64M | -1811.95% |
| Mar 2024 | 202.45K | -4.34M | -2145.25% |
| Mar 2024 | 202.45K | -4.34M | -2145.25% |
|---|---|---|---|
| Sep 2025 | 600K | -4.97M | -828.98% |
| Oct 2025 | 524K | -4.43M | -845.56% |
| Dec 2025 | 424K | -5.00M | -1179.81% |
Analysts Price target
Financials & Ratios estimates
| 2022-11-11 | -0.53 | -0.5 |
|---|---|---|
| 2023-03-17 | -1.3924 | -0.59 |
| Jun 2023 | 4642667 | 6.12M | 131.98% |
|---|---|---|---|
| Sep 2023 | 5597066 | 6.64M | 118.81% |
| Dec 2023 | 13247538 | 8.49M | 64.09% |
| Mar 2024 | 7163890 | 6.55M | 91.48% |
| Jun 2023 | -3.47M | 0 | 3.40M |
|---|---|---|---|
| Sep 2023 | -4.04M | 0 | 5.00M |
| Dec 2023 | -4.29M | -2.42K | 11.74M |
| Mar 2024 | -6.18M | 0 | -69.28K |
Cyclo Therapeutics alternative data
| Aug 2023 | 9 |
|---|---|
| Sep 2023 | 9 |
| Oct 2023 | 9 |
| Nov 2023 | 9 |
| Dec 2023 | 9 |
| Jan 2024 | 9 |
| Feb 2024 | 9 |
| Mar 2024 | 8 |
| Apr 2024 | 8 |
| May 2024 | 8 |
| Jun 2024 | 8 |
| Jul 2024 | 8 |
Cyclo Therapeutics other data
0.30%
-19.90%
of CYTH is owned by hedge funds
19.20K
-1.26M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2023 | 898210 | 0 |
| Aug 2023 | 8000000 | 0 |
| Oct 2023 | 3260482 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | RAFAEL HOLDINGS, INC. 10 percent owner | Warrant to Purchase Common Stock | 2,766,467 | $0.95 | $2,628,144 | ||
Purchase | OSTRONIC FRANCIS PATRICK director | Warrant to Purchase Common Stock | 65,869 | $0.95 | $62,576 | ||
Purchase | SIEGER MARKUS director | Warrant to Purchase Common Stock | 65,869 | $0.95 | $62,576 | ||
Purchase | FINE N SCOTT director, officer.. | Warrant to Purchase Common Stock | 329,342 | $0.95 | $312,875 | ||
Purchase | TATE JEFFREY director, officer.. | Warrant to Purchase Common Stock | 32,935 | $0.95 | $31,288 | ||
Purchase | RAFAEL HOLDINGS, INC. 10 percent owner | Common Stock Warrants (Right to Buy) | 4,000,000 | $1.25 | $5,000,000 | ||
Purchase | RAFAEL HOLDINGS, INC. 10 percent owner | Common Stock, par value $0.0001 per share | 4,000,000 | $1.25 | $5,000,000 | ||
Purchase | TATE JEFFREY director, officer.. | Common Stock | 29,941 | $0.71 | $21,258 | ||
Purchase | TATE JEFFREY director, officer.. | Warrant to Purchase Common Stock | 29,941 | $0.71 | $21,258 | ||
Purchase | FINE N SCOTT director, officer.. | Common Stock | 299,402 | $0.71 | $212,575 |
Alector, INmune Bio, Inflammation, And Alzheimer's Disease: One Piece Of The Puzzle
Hypotheses Underlying Alzheimer's Drug Development
Pathways Impacting Alzheimer's Disease Drug Development
Anti-Amyloid Drugs: The Failure Of Success
Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease
-
What's the price of Cyclo Therapeutics stock today?
One share of Cyclo Therapeutics stock can currently be purchased for approximately $0.72.
-
When is Cyclo Therapeutics's next earnings date?
Unfortunately, Cyclo Therapeutics's (CYTH) next earnings date is currently unknown.
-
Does Cyclo Therapeutics pay dividends?
No, Cyclo Therapeutics does not pay dividends.
-
How much money does Cyclo Therapeutics make?
Cyclo Therapeutics has a market capitalization of 16.86M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 21.76% to 1.08M US dollars. Cyclo Therapeutics made a loss 20.06M US dollars in net income (profit) last year or -$0.59 on an earnings per share basis.
-
What is Cyclo Therapeutics's stock symbol?
Cyclo Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "CYTH".
-
What is Cyclo Therapeutics's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Cyclo Therapeutics?
Shares of Cyclo Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cyclo Therapeutics's key executives?
Cyclo Therapeutics's management team includes the following people:
- Mr. N. Scott Fine Chief Executive Officer & Director(age: 68, pay: $489,200)
- Dr. Sharon H. Hrynkow Ph.D. Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Senior Vice President of Medical Affairs(age: 65, pay: $297,860)
- Dr. Jeffrey L. Tate Chief Operating Officer, Chief Quality Officer & Director(age: 67, pay: $255,140)
-
How many employees does Cyclo Therapeutics have?
As Jul 2024, Cyclo Therapeutics employs 8 workers.
-
When Cyclo Therapeutics went public?
Cyclo Therapeutics, Inc. is publicly traded company for more then 25 years since IPO on 3 May 2000.
-
What is Cyclo Therapeutics's official website?
The official website for Cyclo Therapeutics is cyclotherapeutics.com.
-
Where are Cyclo Therapeutics's headquarters?
Cyclo Therapeutics is headquartered at 6714 NW 16th Street, Gainesville, FL.
-
How can i contact Cyclo Therapeutics?
Cyclo Therapeutics's mailing address is 6714 NW 16th Street, Gainesville, FL and company can be reached via phone at +386 4188060.
Cyclo Therapeutics company profile:
Cyclo Therapeutics, Inc.
cyclotherapeutics.comExchange:
NASDAQ
Full time employees:
8
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
6714 NW 16th Street
Gainesville, FL 32653
Gainesville, FL 32653
CIK: 0000922247
ISIN: US23254X2018
CUSIP: 550241103
